# Nantahala Capital Management

> Nantahala Capital Management is a VC fund backing Biotechnology. See 60 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New Canaan, United States
- Total investments: 60
- Last investment: Aug 2026
- Lead investor: 22%
- Last updated: Aug 2026
- Website: http://www.nantahalapartners.com/

Nantahala Capital Management is a hedge fund.

## Contacts

5 contacts available for Nantahala Capital Management. Shizune tracks 2 team members at Nantahala Capital Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/nantahala-capital-management?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 44 | 73% |
| Health Care | 35 | 58% |
| Pharmaceutical | 20 | 33% |
| Medical | 18 | 30% |
| Therapeutics | 17 | 28% |

25 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 48 | 80% |
| Series B | 1 | 2% |
| Series C | 1 | 2% |
| Post-IPO Debt | 1 | 2% |
| Venture - Series Unknown | 1 | 2% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 43 | 72% |
| Canada | 2 | 3% |
| Israel | 2 | 3% |
| France | 1 | 2% |
| Norway | 1 | 2% |

7 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Paul Rehm | Chief Operating Officer | 0 | https://shizune.co/investors/profile/paul-rehm-5d24 |
| Wilmot Harkey | Founder & Partner | 0 | https://shizune.co/investors/profile/wilmot-harkey |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Femasys | Femasys is a biomedical company focused on transforming women’s healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patientcare and health economics: FemBloc, a first and only non-surgical product for permanent birth control and FemaSeed, a first and only directed sperm delivery product for infertility treatment. Femasys’ FemVue product for fallopian tube assessment by ultrasound is currently marketed in the United States as its main commercial priority. Femasys has also developed a novel technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician’s office setting. | $30M | Post-IPO Equity | Aug 07, 2026 |  |
| Cellectar Biosciences | Cellectar Biosciences, a radiopharmaceutical company, designs and develops products to detect, treat, and monitor various human cancers. Its products include 131I-CLR1404, a compound for cancer therapy. The company's product candidates combine lipid-like molecules and phospholipid ethers analogs with radioisotopes to image or destroy malignantcells.Cellectar Biosciences was formerly known as Cellectar, LLC and changed its name in 2008. The company was founded in 2003 and is based in Madison, Wisconsin. | $35M | Post-IPO Equity | May 05, 2026 |  |
| Cellectar Biosciences | Cellectar Biosciences, a radiopharmaceutical company, designs and develops products to detect, treat, and monitor various human cancers. Its products include 131I-CLR1404, a compound for cancer therapy. The company's product candidates combine lipid-like molecules and phospholipid ethers analogs with radioisotopes to image or destroy malignantcells.Cellectar Biosciences was formerly known as Cellectar, LLC and changed its name in 2008. The company was founded in 2003 and is based in Madison, Wisconsin. | $35M | Post-IPO Equity | May 05, 2026 |  |
| Valneva | Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize two vaccines successfully and torapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19. | $43.1M | Post-IPO Equity | Apr 30, 2026 |  |
| Azitra | Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory,is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis. | $31M | Post-IPO Equity | Mar 19, 2026 |  |
| Korro Bio | Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in proteinstructure and function across multiple tissues.In 2018, | $85M | Post-IPO Equity | Mar 09, 2026 |  |
| LB Pharmaceuticals | LB Pharmaceuticals is a development stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed in the United States. Its approach is to create a research-focused organization dedicated to generating novel intellectual propertyaround improved versions of these former best-selling drugs. The Company's lead asset is LB-102 (n-Methyl amisulpride) a novel, patented version of amisulpride, one of the most effective drugs ever developed for the treatment of schizophrenia. | $100M | Post-IPO Equity | Feb 05, 2026 |  |
| Curis | Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previousexperiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com. | $80.8M | Post-IPO Equity | Jan 07, 2026 |  |
| TELA Bio | TELA Bio is a life science company that specializes in soft tissue reconstruction. The company aims to commercialize a portfolio of products that are purposefully designed to address a range of unmet needs in soft tissue repair. | $13M | Post-IPO Equity | Nov 13, 2025 |  |
| Opus Genetics(formerly Ocuphire Pharma) | Ocuphire Pharma is a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. It is currently focused on providing a novel once-daily eye drop treatment option, Nyxol, to treat multiple front-of-the-eye disorders, including night visiondisturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of their strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes and to seek strategic partners for global commercialization.The company was founded in 2018 and is headquartered in Farmington Hills, Michigan. | $23M | Post-IPO Equity | Nov 06, 2025 |  |

10 of 60 investments shown.

## Co-investors
- [Stonepine Capital Management](https://shizune.co/investors/profile/stonepine-capital-management) — VC Fund, 13 deals together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 12 deals together
- [Samsara BioCapital](https://shizune.co/investors/profile/samsara-biocapital) — VC Fund, 7 deals together
- [Balyasny Asset Management](https://shizune.co/investors/profile/balyasny-asset-management) — VC Fund, 6 deals together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 6 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 6 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Nantahala Capital Management invest in?

Nantahala Capital Management invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Post-IPO Equity and Series B stage. Most of the 60 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Nantahala Capital Management?

Public channels for Nantahala Capital Management include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Nantahala Capital Management?

The team at Nantahala Capital Management includes Paul Rehm (Chief Operating Officer) and Wilmot Harkey (Founder & Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co